| Summary: | The discovery and clinical validation of biomarkers predictive of the response of non-squamous non-small-cell lung carcinomas (NS-NSCLC) to therapeutic strategies continue to provide new data. The evaluation of novel treatments is based on molecular analyses aimed at determining their efficacy. These tests are increasing in number, but the tissue specimens are smaller and smaller and/or can have few tumor cells. Indeed, in addition to tissue samples, complementary cytological and/or blood samples can also give access to these biomarkers. To date, it is recommended and necessary to look for the status of five genomic molecular biomarkers (<i>EGFR</i>, <i>ALK</i>, <i>ROS1</i>, <i>BRAFV600</i>, <i>NTRK</i>) and of a protein biomarker (PD-L1). However, the short- and more or less long-term emergence of new targeted treatments of genomic alterations on <i>RET</i> and <i>MET</i>, but also on others’ genomic alteration, notably on <i>KRAS</i>, <i>HER2</i>, <i>NRG1</i>, <i>SMARCA4</i>, and <i>NUT</i>, have made cellular and blood samples essential for molecular testing. The aim of this review is to present the interest in using cytological and/or liquid biopsies as complementary biological material, or as an alternative to tissue specimens, for detection at diagnosis of new predictive biomarkers of NS-NSCLC.
|
|---|
